Lane Wagnon
Adult Health · Conway, ARNPI 1871756395
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 225 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations.
Across 225 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$641
- Merck$516
- Pfizer$463
- AstraZeneca$346
- Amgen$279
- Actelion Pharmaceuticals US, Inc.$258
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,84898%
- Education$852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 43 | $641 |
| Merck | 31 | $516 |
| Pfizer | 30 | $463 |
| AstraZeneca | 19 | $346 |
| Amgen | 20 | $279 |
| Actelion Pharmaceuticals US, Inc. | 9 | $258 |
| Boehringer Ingelheim | 10 | $230 |
| Sanofi-aventis U.S. LLC | 10 | $195 |
| Lexicon Pharmaceuticals, Inc. | 8 | $167 |
| Medtronic | 1 | $114 |
| E.r. Squibb & Sons, L.L.C. | 7 | $114 |
| Johnson & Johnson | 7 | $107 |
| Bridgebio Pharma, Inc. | 5 | $88 |
| Novo Nordisk | 5 | $82 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $72 |
| Abbott | 3 | $68 |
| Philips North America LLC | 4 | $62 |
| Scpharmaceuticals Inc. | 2 | $38 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $32 |
| Boston Scientific | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Baxter Healthcare | 1 | $13 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MyCareLink$114
How this compares
$3,933 in reported general payments places this provider in the 85th percentile of 154 adult health providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 510 | $378,928 |
| EntrestoSacubitril/Valsartan | 331 | $290,460 |
| XareltoRivaroxaban | 171 | $115,288 |
| JardianceEmpagliflozin | 166 | $114,184 |
| FarxigaDapagliflozin Propanediol | 83 | $51,942 |
| MultaqDronedarone Hcl | 37 | $38,423 |
| VerquvoVericiguat | 12 | $8,980 |
| Ranolazine ErRanolazine | 105 | $8,163 |
| Metoprolol Succinate | 534 | $5,969 |
| Valsartan | 197 | $4,659 |
| Carvedilol | 728 | $4,394 |
| Amiodarone Hcl | 136 | $4,100 |
| Rosuvastatin Calcium | 291 | $3,724 |
| Potassium Chloride | 47 | $3,155 |
| Propafenone Hcl | 67 | $2,784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $463 | $378,928510 claims |
| NovartisEntresto | $641 | $290,460331 claims |
| Johnson & JohnsonXarelto | $107 | $115,288171 claims |
| Boehringer IngelheimJardiance | $230 | $114,184166 claims |
| AstraZenecaFarxiga | $346 | $51,94283 claims |
| Sanofi-aventis U.S. LLCMultaq | $195 | $38,42337 claims |
| MerckVerquvo | $516 | $8,98012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 154 adult health providers in Arkansas.
Other adult health in Conway
- Casey BrockConway$5K
- Felicia JohnsonConway$3K
- Holly GainesConway$2K
- Holly MooreLittle Rock$59K
- Deborah ShipmanJonesboro$41K
- Lisa HurdJonesboro$12K
- Kari SchrankFayetteville$9K
- Amanda McClureFayetteville$9K
- Gina NullFort Smith$8K
- Darren CompasBentonville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.